LoadingLoadingLoading26 funds hold it.Insiders net selling.
Net selling: insiders sold $23.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 27, 2026
Period ending
Sep 30, 2026
Earnings per share
$0.32 expected
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 27, 2026 | $0.56est. $0.32 | +75.00%beat | $286.0MSEC filing | +58.1%from $180.9M |
| Jun 30, 2026Reported Jul 28, 2026 | $0.30est. $0.30 | +0.00%in line | $243.6MSEC filing | +55.4%from $156.8M |
| Mar 31, 2026Reported Apr 28, 2026 | $0.27est. $0.16 | +68.75%beat | $214.3MSEC filing | +55.5%from $137.8M |
| Dec 31, 2025Reported Feb 24, 2026 | $0.17est. $0.40 | -57.50%miss | $202.1MAlpha Vantage | +65.0%from $122.5M |
| Sep 30, 2025Reported Oct 28, 2025 | $0.23est. $0.37 | -37.84%miss | $180.9MSEC filing | +61.2%from $112.2M |
| Jun 30, 2025Reported Jul 29, 2025 | $0.23est. $0.26 | -11.54%miss | $156.8MSEC filing | +44.3%from $108.6M |
| Mar 31, 2025Reported Apr 29, 2025 | $0.11est. $0.28 | -60.71%miss | $137.8MSEC filing | +72.5%from $79.9M |
| Dec 31, 2024Reported Feb 25, 2025 | -$0.12est. $0.02 | -$0.14miss | $122.5MAlpha Vantage | +46.9%from $83.4M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $202.1M | $214.3M | $243.6M | $286.0M |
| Cost of what it sold | $91.1M | $96.4M | $111.6M | $133.6M |
| Gross profit | $111.0M | $117.9M | $132.0M | $152.4M |
| What it spent | ||||
| Research and development | $34.6M | $27.5M | $40.9M | $32.8M |
| Sales and admin | $56.8M | $61.2M | $63.9M | $65.4M |
| Total operating expenses | $91.3M | $88.6M | $104.8M | $98.1M |
| What was left | ||||
| Operating profit | $19.8M | $29.3M | $27.2M | $54.2M |
| Profit before tax | $23.3M | $32.7M | $31.1M | $59.1M |
| Tax | $9.1M | $10.1M | $5.7M | $11.7M |
| Net profit | $14.2M | $22.6M | $25.4M | $47.3M |
| EBITDA | $23.7M | $33.1M | $27.7M | $59.5M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
An officer proposes selling Kiniksa (NASDAQ: KNSA) shares acquired through a cashless option exercise.
Leans bearishNov 2A proposed sale of 553,794 Kiniksa (KNSA) shares includes 377,000 from an option exercise.
NeutralOct 31An officer proposes selling 96,000 Kiniksa (KNSA) shares tied to an option exercise.
NeutralOct 31An officer proposes selling Kiniksa (KNSA) shares, including 97,572 from an option exercise.
NeutralOct 31Form 144 Kiniksa Pharmaceuticals International For: 30 October By Investing.com
NeutralOct 31Form 144 Kiniksa Pharmaceuticals International For: 30 October By Investing.com
NeutralOct 30After selling 4,600 shares, Kiniksa (KNSA) officer Michael R. Megna proposes another sale.
Leans bearishOct 30Profit rises from $18.4M to $47.3M as Kiniksa (KNSA) product revenue climbs.
BullishOct 28
